



- Agonists:



- **Antagonists:** are substances or molecules that bind to the receptor and prevent agonists from binding to it. Therefore, it will inhibit the action of agonists on the receptor.



The difference between these two types of antagonists is:

1. The competitive ↓ the agonist potency
2. The non-competitive ↓ the agonist efficacy

Physiological/Functional antagonism: initiates effects that are functionally opposite those of the agonist.


Chemical antagonist: prevents the action of an agonist by modifying the agonist so it is unable to bind to its receptor and activate it.

Pharmacokinetic antagonism: a situation in which antagonism reduces the active [drug].

And this can occur when: the absorption ↓s, or when the metabolism and renal excretion ↑s.

Introduction to Cholinergic & Adrenergic Fibers

- **Cholinergic fibers** are those that secrete Acetylcholine
- **Adrenergic fibers** are those that secrete Norepinephrine



I. Cholinergic Neurons:


- **Neurotransmission at cholinergic neurons:**

Involves 6 steps: “the picture below sums them all up”


1. Synthesis of Acetylcholine (ACh): ***The uptake of choline** is the rate-limiting step*
2. Storage of ACh.
3. Release of ACh.
4. Binding of ACh to its receptor
5. Degradation of ACh

***NOTE:** the enzyme **Butyrylcholinesterase**, (known also as **pseudo cholinesterase**, is found in the plasma but does not play a significant role in the termination of ACh’s effect in the synapse.

6. Recycling of Choline




- **Cholinergic receptors (Cholinoceptors):**



A. Muscarinic Receptors:

- It can recognize ACh and Muscarine (an alkaloid present in poisonous mushrooms).
- If M₁ or M₃ are activated:




- If M₂ is activated:

It will interact with G-protein (G_i) → - cAMP & ↑ K⁺ conductance → ↓ rate/force of ♥ contractility

B. Nicotinic Receptors:

- Binding of two ACh molecules elicits a conformational change that allows the entry of Na⁺, resulting in depolarization of the effector cell.
- These receptors are located in the CNS, adrenal medulla, autonomic ganglia, and neuromuscular junction.

- **Cholinergic Agonists Drugs: (aka parasympathomimetics):**



Direct-acting Agonists Drugs:

- Have longer durations than ACh
 - Show little specificity in their actions, which limits their clinical usefulness.
1. **ACETYLCHOLINE:** (same as parasympathetic effects: on many organs)
- ★ Check Pharmacology Recall, 2nd edition, pages 36-37 ★
2. **CARBACHOL:**
- ★ Check Pharmacology Recall, 2nd edition, page 37 ★
3. **PILOCARPINE:** This drug can enter the brain and cause CNS disturbances along with **DUMBELS**.
- ★ Check Pharmacology Recall, 2nd edition, page 38 ★

	Receptor(s) it activates	Adverse Effects
Acetylcholine	Both muscarinic & nicotinic	Excessive generalized cholinergic stimulation: DUMBELS Diarrhea & Decreased BP Urination Miosis Bronchoconstriction & Bradycardia Excitation of skeletal muscles Lacrimation Salivation & Sweating
Carbachol	Both muscarinic & nicotinic and it can also release epinephrine & norepinephrine from the adrenal medulla	
Pilocarpine	Muscarinic receptors	

Indirect- acting Agonists Drugs:

4. **NEOSTIGMINE:** reversible.


★ Check Pharmacology Recall, 2nd edition, pages 40-42 ★

5. **PARATHION:** irreversible.

★ Check Pharmacology Recall, 2nd edition, pages 39-40 ★

*NOTE: **PRALIDOXIME:** is a drug that reactivates acetyl cholinesterase.

- **Cholinergic Antagonist Drugs:** (aka as cholinergic blockers, smpatholytics, and anticholinergic drugs)



A. Antimuscarinic Agents:

1. **ATROPINE: (Antimuscarinic):** “causes sympathetic responses”

It causes reversible, nonselective blockade of muscarinic receptors (to prevent ACh from binding).

★ Check Pharmacology Recall, 2nd edition, pages 43-45 ★

2. **TROPICAMIDE** (short acting atropine):

★ Check Pharmacology Recall, 2nd edition, page 46 ★

B. Ganglionic Blockers:

These drugs block the entire output of the autonomic nervous system at the nicotinic receptor.

C. Neuromuscular-blocking Drugs:

These are clinically useful during surgery for producing complete muscle relaxation, orthopedic surgery, and tracheal intubation.

II. Adrenergic Neurons:

- Neurotransmission at adrenergic neurons:

Involves 5 steps: "refer to the picture below"

1. Synthesis of norepinephrine (NE):

This is the rate-limiting step in the formation of norepinephrine.

2. Storage of NE in vesicles.

3. Release of NE.

4. Binding to receptors.


5. Removal of epinephrine:

By: - diffusing out of the synaptic space & enter the general circulation

- being metabolized by Catechol-O-Methyltransferase (COMT)


-be recaptured by an uptake system (which involves a Na⁺ or K⁺-activated ATPase) which will pump NE back into the neuron.

6. Fates of recaptured NE: it can be oxidized by monoamine oxidase (MAO) present in the neuronal mitochondria.




Done by: Aysha Khalid

- **Adrenergic Receptors (Adrenoceptors):**



- **Activation of α_1 receptors results in:**



- **The α_2 receptors act as:**


***Inhibitory Auto receptors:** when norepinephrine is released from the synaptic vesicle, part of it binds to α_1 receptors and part of it bind to α_2 which are found on the neuronal membrane to inhibit the ongoing release of norepinephrine.

***Inhibitory Heteroreceptors:** sometimes norepinephrine can diffuse to and interact with these receptors to inhibit the release of Acetylcholine.

- **Activation of any one of the three β receptors:** will activate adenylyl cyclase, and therefore, ↑ [cAMP].

-**Major Effects mediated by α & β adrenoceptors:**

α_1	α_2	β_1	β_2
-Vasoconstriction -↑ peripheral resistance -↑BP -Mydriasis -↑ closure of internal sphincter of bladder	-↓ of NE release -↓ of ACh release -↓ of insulin release	-Tachycardia -↑lipolysis -↑ myocardial contractility -↑ release of renin	-Vasodilation -↓ peripheral resistance -Bronchodilation -↑ glycogenolysis -↑ release of glucagon -Relaxed uterine smooth muscle



-Desensitization of receptors:

Prolonged exposure to the catecholamine ↓ the responsiveness of these receptors (Desensitization): and this can be explained by:

1. Sequestration of the receptors so they are not available for interaction
2. Down-regulation (disappearance of the receptors by destruction or ↓ synthesis)
3. Inability to couple to G- protein because it has been “+P”

-Characteristics of adrenergic agonists:

Most of the adrenergic drugs are derivates of β-phenylethylamine

Important structural features of these drugs are:

1. The # and location of OH molecules on the benzene ring
2. The nature of the molecule on the amino nitrogen.

A. **Catecholamines:** are sympathomimetic amines that contain 3,4-dihydroxybenzene (eg. Epinephrine, norepinephrine, dopamine, and isoproterenol).


These have the following properties:

- a. High potency: in directly activating α & β receptors.
 - b. Rapid interaction: due to the fact that they get metabolized by the enzymes MAO & COMT
 - c. Poor penetration into the CNS: because they are polar
- B. **Noncatecholamines:** are compounds that lack the catechol hydroxyl groups (eg. Phenylephrine, ephedrine, and amphetamine)

These have a longer half-lives because they are not inactivated by COMT

They may penetrate the CNS because they have an increased lipid solubility (due to the lack of polar OH groups)

- Mechanisms of action of the adrenergic agonist drugs:



-Direct- Acting Adrenergic Agonists:

1. EPINEPHRINE:

★ Check Pharmacology Recall, 2nd edition, pages 57-58 ★

Pharmacokinetics:

Has a rapid onset but a brief duration of action so its better to give it intramuscularly.

2. NOREPINEPHRINE:

★ Check Pharmacology Recall, 2nd edition, pages 58-59 ★

Pharmacokinetics:

It may be given IV for rapid onset

Indirect-Acting Adrenergic Agonists:

3. AMPHETAMINE:

★ Check Pharmacology Recall, 2nd edition, page 60 ★

Mixed-Actions Adrenergic Agonists:

4. EPHEDRINE:

★ Check Pharmacology Recall, 2nd edition, page 61 ★

- **Adrenergic Antagonist Drugs:** (aka blockers or sympatholytic agents): bind to adrenoceptors but do not make the usual receptor-mediated intracellular effects.

These are also further classified into reversible and irreversible antagonists.

A. α -adrenergic blocking agents:

These affect the blood pressure the most because they \downarrow the sympathetic tone of the blood vessels, that will result in \downarrow peripheral vascular resistance.

5. PRAZOSIN: selective competitive blocker

Its useful in treating hypertensive patients

★ Check Pharmacology Recall, 2nd edition, page 63 ★

B. β -adrenergic blocking agents: (competitive agonists)

Non-selective blockers \rightarrow work on both β_1 & β_2 receptors

Cardioselective β antagonists primarily block β_1 receptors.

The names of these types of drugs end in “-olol”

6. PROPRANOLOL:

Pharmacokinetics:

After oral administration, this drug is totally absorbed because its highly lipophilic.

It can cross the blood-brain barrier

★ Check Pharmacology Recall, 2nd edition, pages 66-67 ★